A Phase 3 interventional study of Eravacycline and Ertapenem in Complicated Urinary Tract Infections, sponsored by Tetraphase Pharmaceuticals, Inc.. Completed at 71 sites in 12 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-01-06.
Sponsored by Tetraphase Pharmaceuticals, Inc. · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies in Urinary Tract Infections with a site in Ukraine — none open to participants now, none under way, none of them phase 3. Urinary Tract Infections · Ukraine.
Among the 11 studies in Urinary Tract Infections with a site in Ukraine, this one is the 2nd largest by enrollment, is one of 2 that started in 2017, is one of 9 in phase 3, and was the 7th registered.
804 studies on the registry are indexed under Urinary Tract Infections; 133 are open to participants now.
Browse Urinary Tract Infections studies →None of the 11 studies in Urinary Tract Infections with a site in Ukraine is open now. The open studies under Urinary Tract Infections, anywhere →
Of the 84 Urinary Tract Infections studies recruiting now, 50 (60%) set no upper age limit and 23 (27%) stop at 75 or younger; 15 take children under 18; 17 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 2 · Phase 3 10
First in 2011; this study’s year is marked. 2 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,205 is above the median of 132 across 561 interventional studies indexed under Urinary Tract Infections.
Median enrollment 598 across the 11 interventional studies. Of the 11 that completed or were terminated, 9 (82%) have results posted.
This tab as a report to print or save as PDF → With an account.
11 of 11 have an industry lead sponsor. The 8 most frequent:
Tetraphase Pharmaceuticals, Inc. is the lead sponsor of 15 studies on the registry; none are open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 2 (33%) have results posted.
Tetraphase Pharmaceuticals, Inc. has 1 study filed under Urinary Tract Infections — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 11 studies in Urinary Tract Infections with a site in Ukraine, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to assess the efficacy, safety, and pharmacokinetics of eravacycline compared to ertapenem in treating participants with complicated urinary tract infections (cUTI).
The purpose of this study is to assess the efficacy, safety, and pharmacokinetics of eravacycline compared to ertapenem in treating participants with complicated urinary tract infections (cUTI).
This is a phase 3, randomized, double-blind, double-dummy, multicenter, prospective study to assess the efficacy, safety and pharmacokinetics of eravacycline compared with ertapenem in the treatment of cUTI.
Randomization will be stratified based on two criteria: (1) by primary site of infection (pyelonephritis and normal urinary tract anatomy vs all other diagnoses) and (2) by the receipt of a single dose of effective non-study antibiotics for the acute cUTI within 72 hours prior to randomization. An enrollment cap of approximately 50% is planned for subjects with pyelonephritis with normal urinary tract anatomy. Also, an enrollment cap of approximately 20% is planned for subjects who have received a single dose of non-study antibiotics for the acute cUTI within 72 hours prior to randomization.
In this study subjects will be enrolled and randomized to one of two treatment arms in a 1:1 ratio: (i) eravacycline intravenously (IV) / levofloxacin (PO), or (ii) ertapenem (IV) / levofloxacin (PO).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Male or female participant with either:
cUTI with at least one of the following conditions associated with a risk for developing cUTI:
At least two of the following signs or symptoms:
Urine specimen with evidence of pyuria
Exclusion Criteria:
Use of systemic antibiotics effective in cUTI within 72 hours prior to enrollment except under the following circumstances:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CD4 count
The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Eravacycline · Drug: Placebo · Drug: Levofloxacin
Drug: Ertapenem · Drug: Placebo · Drug: Levofloxacin
Also known as: TP-434
Also known as: Invanz
Also known as: Levaquin
Proportion of Participants in the Micro-ITT Population Demonstrating Clinical Cure and Microbiologic Success at the EOI Visit
This was the co-primary outcome measure for the Food and Drug Administration (FDA). The primary objective was to demonstrate the non-inferiority (NI) of eravacycline to ertapenem in responder outcome, which was derived from both clinical and microbiological responses, in the micro-ITT population. Clinical responses were either cure, failure, or indeterminate/missing; microbiological responses were characterized programmatically as either success, failure, or indeterminate/missing. Clinical cure was defined as complete resolution or significant improvement of signs or symptoms of the infection; microbiological success was a reduction of the baseline pathogen(s) to \<10\^4 colony-forming units/milliliter (CFU/mL). An outcome of Responder required a clinical response of cure and a microbiological response of success. Any other combination of the clinical and microbiological responses was considered either Non-responder or Indeterminate.
Time frame: End of Infusion
Proportion of Participants in the Micro-ITT Population Demonstrating Clinical Cure and Microbiologic Success at the Test-Of-Cure (TOC) Visit
This was the co-primary outcome measure for the Food and Drug Administration (FDA). The primary objective was to demonstrate the non-inferiority (NI) of eravacycline to ertapenem in responder outcome, which was derived from both clinical and microbiological responses, in the micro-ITT population. Clinical responses were either cure, failure, or indeterminate/missing; microbiological responses were characterized programmatically as either success, failure, or indeterminate/missing. Clinical cure was defined as complete resolution or significant improvement of signs or symptoms of the infection; microbiological success was a reduction of the baseline pathogen(s) to \<10\^4 colony-forming units/milliliter (CFU/mL). An outcome of responder required a clinical response of cure and a microbiological response of success. Any other combination of the clinical and microbiological responses was considered either Non-responder or Indeterminate.
Time frame: TOC visit (14-17 days after randomization)
Proportion of Participants in the ITT Population With Favorable Clinical Outcomes at TOC Visit
Clinical cure: A complete resolution or significant improvement of signs or symptoms of the infection such that no rescue/non-study antibacterial medication was required to treat the cUTI that presented at study entry. Clinical failure: Subjects were classified as clinical failure in the event of * Death related to cUTI at any timepoint * Persistence of clinical symptoms of cUTI or new symptoms developed * Initiation of rescue/non-study antibacterial medication for cUTI Indeterminate: Study data were listed as indeterminate if the outcome was other than clinical cure or clinical failure. The reason for an indeterminate designation had to be provided Missing: Study data were listed as missing if the Investigator did not complete an assessment or if the subject did not complete the study visit.
Time frame: TOC visit (14-17 days after randomization)
| Milestone | Eravacycline (Intravenous)/Levofloxacin (Oral) | Ertapenem (Intravenous)/Levofloxacin (Oral) |
|---|---|---|
| Started | 603 | 602 |
| Completed | 576 | 584 |
| Not completed | 27 | 18 |
| Withdrew: Adverse event | 5 | 2 |
| Withdrew: Lost to follow-up | 8 | 7 |
| Withdrew: Withdrawal by subject | 8 | 7 |
| Withdrew: Subject noncompliance | 4 | 2 |
| Withdrew: Physician decision | 2 | 0 |
This was the co-primary outcome measure for the Food and Drug Administration (FDA). The primary objective was to demonstrate the non-inferiority (NI) of eravacycline to ertapenem in responder outcome, which was derived from both clinical and microbiological responses, in the micro-ITT population. Clinical responses were either cure, failure, or indeterminate/missing; microbiological responses were characterized programmatically as either success, failure, or indeterminate/missing. Clinical cure was defined as complete resolution or significant improvement of signs or symptoms of the infection; microbiological success was a reduction of the baseline pathogen(s) to \<10\^4 colony-forming units/milliliter (CFU/mL). An outcome of Responder required a clinical response of cure and a microbiological response of success. Any other combination of the clinical and microbiological responses was considered either Non-responder or Indeterminate.
| Participants | Eravacycline (Intravenous) | Ertapenem (Intravenous) |
|---|---|---|
| Responder | 363 | 382 |
| Non-responder | 51 | 7 |
| Indeterminate | 14 | 14 |
This was the co-primary outcome measure for the Food and Drug Administration (FDA). The primary objective was to demonstrate the non-inferiority (NI) of eravacycline to ertapenem in responder outcome, which was derived from both clinical and microbiological responses, in the micro-ITT population. Clinical responses were either cure, failure, or indeterminate/missing; microbiological responses were characterized programmatically as either success, failure, or indeterminate/missing. Clinical cure was defined as complete resolution or significant improvement of signs or symptoms of the infection; microbiological success was a reduction of the baseline pathogen(s) to \<10\^4 colony-forming units/milliliter (CFU/mL). An outcome of responder required a clinical response of cure and a microbiological response of success. Any other combination of the clinical and microbiological responses was considered either Non-responder or Indeterminate.
| Participants | Eravacycline | Ertapenem |
|---|---|---|
| Responder | 293 | 302 |
| Non-responder | 116 | 86 |
| Indeterminate | 19 | 15 |
Clinical cure: A complete resolution or significant improvement of signs or symptoms of the infection such that no rescue/non-study antibacterial medication was required to treat the cUTI that presented at study entry. Clinical failure: Subjects were classified as clinical failure in the event of * Death related to cUTI at any timepoint * Persistence of clinical symptoms of cUTI or new symptoms developed * Initiation of rescue/non-study antibacterial medication for cUTI Indeterminate: Study data were listed as indeterminate if the outcome was other than clinical cure or clinical failure. The reason for an indeterminate designation had to be provided Missing: Study data were listed as missing if the Investigator did not complete an assessment or if the subject did not complete the study visit.
| Participants | Eravacycline (Intravenous)/Levofloxacin (Oral) | Ertapenem (Intravenous)/Levofloxacin (Oral) |
|---|---|---|
| Clinical Cure | 547 | 566 |
| Clinical Failure | 31 | 20 |
| Indeterminate/missing | 25 | 16 |
Collected over The time frame for adverse event reporting was from the first dose of study drug through 30 days after the last dose of study drug or the FU visit (whichever was later).. Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Eravacycline (Intravenous) | 3/601 (0.5%) | 11/601 (1.8%) | 174/601 (29%) |
| Ertapenem (Intravenous) | 2/600 (0.3%) | 6/600 (1%) | 52/600 (8.7%) |
| Event | Eravacycline (Intravenous) | Ertapenem (Intravenous) |
|---|---|---|
| Cerebrovascular accidentNervous system disorders | 2/601 | 0/600 |
| Aneurysm rupturedVascular disorders | 2/601 | 1/600 |
| Cardiorenal syndromeCardiac disorders | 0/601 | 1/600 |
| HaemorrhoidsGastrointestinal disorders | 0/601 | 1/600 |
| Clostridium difficile colitisInfections and infestations | 0/601 | 1/600 |
| Renal abscessInfections and infestations | 0/601 | 1/600 |
| MeningiomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/601 | 1/600 |
| Circulatory collapseVascular disorders | 0/601 | 1/600 |
| Acute myocardial infarctionCardiac disorders | 1/601 | 0/600 |
| Myocardial infarctionCardiac disorders | 1/601 | 0/600 |
| Event | Eravacycline (Intravenous) | Ertapenem (Intravenous) |
|---|---|---|
| NauseaGastrointestinal disorders | 84/601 | 10/600 |
| VomitingGastrointestinal disorders | 31/601 | 4/600 |
| Infusion site phlebitisGeneral disorders | 24/601 | 3/600 |
| HeadacheGeneral disorders | 17/601 | 18/600 |
| DiarrhoeaGastrointestinal disorders | 18/601 | 17/600 |
| Age, Categorical(Participants) | Eravacycline (Intravenous)/Levofloxacin (Oral) | Ertapenem (Intravenous)/Levofloxacin (Oral) | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 338 | 331 | 669 |
| >=65 years | 265 | 271 | 536 |
| Age, Continuous(years) | Eravacycline (Intravenous)/Levofloxacin (Oral) | Ertapenem (Intravenous)/Levofloxacin (Oral) | Total |
|---|---|---|---|
| Mean | 57.1 ± 18.16 | 56.5 ± 19.34 | 56.8 ± 18.7 |
| Sex: Female, Male(Participants) | Eravacycline (Intravenous)/Levofloxacin (Oral) | Ertapenem (Intravenous)/Levofloxacin (Oral) | Total |
|---|---|---|---|
| Female | 330 | 343 | 673 |
| Male | 273 | 259 | 532 |
| Ethnicity (NIH/OMB)(Participants) | Eravacycline (Intravenous)/Levofloxacin (Oral) | Ertapenem (Intravenous)/Levofloxacin (Oral) | Total |
|---|---|---|---|
| Hispanic or Latino | 11 | 15 | 26 |
| Not Hispanic or Latino | 592 | 587 | 1179 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Eravacycline (Intravenous)/Levofloxacin (Oral) | Ertapenem (Intravenous)/Levofloxacin (Oral) | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 1 | 0 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 2 | 1 | 3 |
| White | 600 | 601 | 1201 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Region of Enrollment(participants) | Eravacycline (Intravenous)/Levofloxacin (Oral) | Ertapenem (Intravenous)/Levofloxacin (Oral) | Total |
|---|---|---|---|
| Latvia | 36 | 39 | 75 |
| Austria | 0 | 1 | 1 |
| Romania | 54 | 59 | 113 |
| Hungary | 56 | 66 | 122 |
| United States | 9 | 13 | 22 |
| Ukraine | 148 | 137 | 285 |
| Georgia | 33 | 40 | 73 |
| Slovakia | 18 | 13 | 31 |
| Bulgaria | 61 | 42 | 103 |
| Estonia | 21 | 20 | 41 |
| Russia | 126 | 143 | 269 |
| Poland | 23 | 17 | 40 |
| Moldova | 18 | 12 | 30 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Jan 2017 to primary completion in Dec 2017, 11 months.
Results were first posted in Oct 2019, 1 year 10 months after primary completion.
Of 23 industry-sponsored phase 3 interventional studies under Urinary Tract Infections, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 28. This study's 11 months is below that.
Counting every sponsor, half of 37 studies reached it within 20 months; a quarter within 14 and three quarters within 32.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Eravacycline
Tetraphase Pharmaceuticals, Inc.